EL7.AI
StocksMedium•19 October 2026•
4 min read

Disc Medicine Announces Proposed $350 Million Offering to Support Drug Development

Key Facts

1Disc Medicine announced a proposed $350 million public offering comprising common shares and pre-funded warrants.
2The company held $717.7 million in cash, cash equivalents and marketable securities as of June 30, 2026.
3APollo showed a 41.4% reduction in whole-blood metal-free protoporphyrin versus placebo.
4The company plans to resubmit its new drug application for bitopertin to the U.S. Food and Drug Administration by the end of 2026.

Disc Medicine announced the launch of a proposed $350 million public offering, with preparations for the potential commercialization of its investigational drug bitopertin among the stated uses of proceeds. The company said in its offering statement that the transaction comprises common shares and pre-funded warrants offered in lieu of shares to certain participating investors. Disc Medicine itself will sell all the shares and warrants offered, making the proposed transaction a source of funding for the company for its specified uses. Jefferies, Leerink Partners, Morgan Stanley and Cantor are acting as joint book-running managers, according to the statement. The financing move coincides with the announcement of results from the APollo trial of bitopertin, as the company works toward resubmitting its application for U.S. approval of the drug.

The company intends to use the net proceeds from the offering, together with its existing resources, to fund research and clinical development, according to its statement outlining the intended uses of the financing. These uses include supporting the potential commercialization of bitopertin to treat erythropoietic protoporphyria and the X-linked form. Disc Medicine also identified commercial preparations for other drug candidates among the expenditures it intends to fund with the proceeds and its available resources. The stated uses of the funds extend to working capital and general corporate purposes, alongside development and commercial preparation activities for its therapeutic candidates. Plans to commercialize bitopertin remain contingent on regulatory approval, as the company confirmed in its APollo results announcement that the drug is investigational and has not been approved for therapeutic use in any jurisdiction worldwide.

Disc Medicine had reported cash, cash equivalents and marketable securities of $717.7 million in its financial results for the period ended June 30, 2026. In its financial guidance preceding the proposed offering, the company estimated that its reported resources would fund its operating plans into 2029. Those resources included cash and marketable securities held when the results were announced, while the new offering aims to raise additional funds for the uses specified in its statement. In the same earlier update, the company announced alignment with the U.S. Food and Drug Administration on the potential use of the successful APollo trial in responding to the complete response letter. It said this pathway could support potential traditional approval of bitopertin as part of the regulatory work on the drug application.

The APollo trial enrolled 183 patients, according to Disc Medicine's announcement, and used a randomized, double-blind design comparing bitopertin treatment with placebo. Results showed a 41.4% reduction in whole-blood metal-free protoporphyrin versus placebo, according to the comparison reported by the company. For time patients spent in light without pain, the trial recorded an increase in mean total monthly time among bitopertin recipients compared with placebo recipients. This increase reached 12.2 hours in the sixth month, the assessment point specified by the company for this outcome in its APollo trial announcement. The company reported a p-value of 0.0010 for this comparison, alongside the whole-blood protoporphyrin finding, in its presentation of clinical results for the investigational drug.

On safety, Disc Medicine said the APollo trial showed "no new safety signals" for bitopertin, according to the statement announcing the study results. The company had launched an expanded access program allowing access to the drug before a regulatory decision, according to its earlier update accompanying its financial results. The program targets eligible patients, providing treatment through this pathway in the United States, within the scope announced by the company. The program also extends to other selected regions, allowing access to bitopertin before a decision on its application for approval for therapeutic use. The program is part of the company's activities relating to the drug, alongside the APollo trial and work on the regulatory response that it said could be based on the successful study results.

Completion of the offering remains "subject to market and other conditions," according to Disc Medicine's statement, with those conditions also applying to the transaction's actual size and final terms. The company gave no assurance that the offering would be completed or when, with the announced amount remaining a proposed size for the transaction it has launched. On the regulatory pathway for bitopertin, the company plans to resubmit its new drug application to the U.S. Food and Drug Administration by the end of 2026. That target follows the announcement of APollo results and forms part of the pathway the company discussed with the agency to respond to the complete response letter and support potential traditional approval. Disc Medicine expects an FDA decision on bitopertin by mid-2027, according to the timeline it announced with the trial results.